Compare Paychex, Inc. (PAYX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Repligen Corporation Common Stock — how do they compare? Paychex, Inc. trades at $110 (market cap $38.58B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Paychex, Inc. is far larger — about 3.4× Repligen Corporation Common Stock's market cap, and Paychex, Inc. pays a 4.39% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Repligen Corporation Common Stock for 0 Days on average.
| PAYX | RGEN | |
|---|---|---|
Market Cap | $38.58B | $11.31B |
Volume | 2,721,004 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $127.54 | $194.57 |
52-Week Low | $85.57 | $102.87 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $42.26B | $11.20B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $106.26, up 1.55% today, with a bullish technical signal despite some bearish moving average indicators. The company reported a beat on Q2 2026 EPS of $1.34 versus $1.32 expected, continuing a trend of earnings outperformance. Revenue grew to $5.57B in 2025, with strong profitability margins including a 27.35% net income margin and 47.06% ROE. Recent news highlights dividend sustainability concerns amid a stock price decline, though the company maintains a solid financial position.
The outlook for PAYX is mixed; fundamentals remain robust with consistent earnings beats and high profitability, but investor sentiment is cautious due to valuation concerns and labor market exposure. Near-term price action hinges on Q3 2026 earnings and dividend coverage metrics. Risks include economic sensitivity and competitive pressures, while analyst consensus suggests modest upside to a $111 price target.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
